The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies

2009/04/22 by Douglas D. Banks, David M. Hambly, Joanna L. Scavezze +4 · 22 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Protein purification and stability #Viral Infectious Diseases and Gene Expression in Insects #Monoclonal and Polyclonal Antibodies Research

paper · doi:10.1002/jps.21749

Citations

• The LC/MS Analysis of Glycation of IGG Molecules in Sucrose Containing Formulations

Cited by

• Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. [europepmc]
• Non-Arrhenius protein aggregation. [europepmc]
• Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. [europepmc]
• In vitro and in vivo modifications of recombinant and human IgG antibodies. [europepmc]
• Glycation of antibodies: Modification, methods and potential effects on biological functions. [europepmc]
• Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches. [europepmc]
• Forced degradation of recombinant monoclonal antibodies: A practical guide. [europepmc]
• Quantitative analysis of glycation and its impact on antigen binding. [europepmc]
• Analytical comparability study of recombinant monoclonal antibody therapeutics. [europepmc]
• Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. [europepmc]
• Structure, heterogeneity and developability assessment of therapeutic antibodies. [europepmc]
• Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. [europepmc]
• Comprehensive Assessment of Protein and Excipient Stability in Biopharmaceutical Formulations Using 1 H NMR Spectroscopy. [europepmc]
• Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants. [europepmc]
• Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins. [europepmc]
• Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. [europepmc]
• Region-selective and site-specific glycation of influenza proteins surrounding the viral envelope membrane. [europepmc]
• Developability considerations for bispecific and multispecific antibodies. [europepmc]
• Understanding the Role of Polyols and Sugars in Reducing Aggregation in IgG 2 and IgG 4 Monoclonal Antibodies During Low-pH Viral Inactivation Step. [europepmc]
• Systematic characterization of lysine glucuronidation in a bispecific antibody. [europepmc]
• Potential of Time Domain Nuclear Magnetic Resonance as a Noninvasive Method for Detection and Quantification of Protein Glycation in Biopharmaceuticals. [europepmc]
• Prediction and Characterization of Glycated Peptides and Proteins using Hydrophilic Interaction Liquid Chromatography coupled with Mass Spectrometry (HILIC-MS). [europepmc]